Napredna pretraga

Pregled bibliografske jedinice broj: 193680

Dopamine agonist prevent duodenal ulcer relapse, A comparative study with famotidine and cimetidine


Sikirić, Predrag; Rotkvić, Ivo; Miše, Stjepan; Petek, Marijan; Ručman, Rudolf; Seiwert, Sven; Zjačić-Rotkvić, Vanja; Duvnjak, Marko; Jagić, Vjekoslav; Suchanek, Ernest et al.
Dopamine agonist prevent duodenal ulcer relapse, A comparative study with famotidine and cimetidine // Digestive diseases and sciences, 36 (1991), 7; 905-910 (međunarodna recenzija, članak, znanstveni)


Naslov
Dopamine agonist prevent duodenal ulcer relapse, A comparative study with famotidine and cimetidine

Autori
Sikirić, Predrag ; Rotkvić, Ivo ; Miše, Stjepan ; Petek, Marijan ; Ručman, Rudolf ; Seiwert, Sven ; Zjačić-Rotkvić, Vanja ; Duvnjak, Marko ; Jagić, Vjekoslav ; Suchanek, Ernest ; Grabarević, Željko ; Anić, Tomislav ; Brkić, Tomislav ; Djermanović, Zoran ; Dodig, Milan ; Marović, Anton ; Hernandez, E. Daniel

Izvornik
Digestive diseases and sciences (0163-2116) 36 (1991), 7; 905-910

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Peptid ulcer; H2 blockers; dopamine agonists; relapse rate

Sažetak
The present study investigated both the healing rate (after four weeks) and relapse rate (during six months) following treatment with the dopamine-like drugs bromocriptine (2.5 mg twice daily), amantadine (100 mg nocte), or with H2 blockers cimetidine (800 mg nocte), and famotidine (40 mg nocte) in 124 patients with endoscopically proven duodenal ulcer (DU). The ulcer was completly healed in 27 (amatidine), 26 (bromosriptine), 23 (cimetidine), and 24 (famotidine) patients. Relapse was noted 34.7 % (cimetidine) and 25 % (famotidine) versus 11.7 % (amatidine) and 7.7 % (bromocriptine) DU patients. No significant difference was found in initial healing rates. However, the relapse rate in the cimetidine-treated group was significantly higher than in all the other test groups. Additional comparisons between all the treatment categories showed a signifcantly lower relaps rate with the dopamine-like agents. These important new results indicate that dopamine-like compounds are equally effective as H2 blockers in inducing DU healing and may offer a promising advantage over H2 blockers concerning their efficacy in preventing ulcer relapse in DU patients.

Izvorni jezik
Engleski

Znanstvena područja
Veterinarska medicina

Citiraj ovu publikaciju

Sikirić, Predrag; Rotkvić, Ivo; Miše, Stjepan; Petek, Marijan; Ručman, Rudolf; Seiwert, Sven; Zjačić-Rotkvić, Vanja; Duvnjak, Marko; Jagić, Vjekoslav; Suchanek, Ernest et al.
Dopamine agonist prevent duodenal ulcer relapse, A comparative study with famotidine and cimetidine // Digestive diseases and sciences, 36 (1991), 7; 905-910 (međunarodna recenzija, članak, znanstveni)
Sikirić, P., Rotkvić, I., Miše, S., Petek, M., Ručman, R., Seiwert, S., Zjačić-Rotkvić, V., Duvnjak, M., Jagić, V. & Suchanek, E. (1991) Dopamine agonist prevent duodenal ulcer relapse, A comparative study with famotidine and cimetidine. Digestive diseases and sciences, 36 (7), 905-910.
@article{article, year = {1991}, pages = {905-910}, keywords = {Peptid ulcer, H2 blockers, dopamine agonists, relapse rate}, journal = {Digestive diseases and sciences}, volume = {36}, number = {7}, issn = {0163-2116}, title = {Dopamine agonist prevent duodenal ulcer relapse, A comparative study with famotidine and cimetidine}, keyword = {Peptid ulcer, H2 blockers, dopamine agonists, relapse rate} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE